<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896697</url>
  </required_header>
  <id_info>
    <org_study_id>XTX101-01/02-001</org_study_id>
    <nct_id>NCT04896697</nct_id>
  </id_info>
  <brief_title>XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xilio Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xilio Development, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the&#xD;
      safety and tolerability of XTX101 as monotherapy and XTX101 and pembrolizumab combination&#xD;
      therapy in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the&#xD;
      safety and tolerability of XTX101, a tumor-selective anti-CTLA-4 antibody, as monotherapy and&#xD;
      XTX101 and pembrolizumab combination therapy in patients with advanced solid tumors.&#xD;
&#xD;
      Part 1A will examine XTX101 monotherapy in an accelerated and standard 3+3 dose escalation&#xD;
      design. Based on the results of Part 1A, patients with select advanced solid tumors will be&#xD;
      enrolled in Part 1B, which will evaluate XTX101 monotherapy in relation to specific PD&#xD;
      biomarkers.&#xD;
&#xD;
      Part 1C will examine XTX101 in combination with pembrolizumab in a standard 3+3 dose&#xD;
      escalation design, examining up to 2 dose levels of XTX101 in combination with the labeled&#xD;
      dose of pembrolizumab. After completion of Part 1C, the study will initiate Part 2, examining&#xD;
      the RP2D of XTX101 and pembrolizumab combination therapy in patients with unresectable or&#xD;
      metastatic melanoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs) (Part 1A and Part 1C only)</measure>
    <time_frame>Cycle 1 day 1 up to just prior to the second dose of study drug at Cycle 2 day 1 (approximately 3 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events and changes in clinical laboratory abnormalities (Part 1A, 1B &amp; 1C only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence changes in clinical laboratory (Part 1A, 1B &amp; 1C only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator-assessed objective response rate (ORR) per iRECIST (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed objective response rate (ORR) per iRECIST (Part 1A, 1B &amp; 1C only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibody (ADA) occurrence and titer in serum (Part 1A, 1B &amp; 1C only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of XTX101 (total and intact)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations (Ctrough)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>Up to Cycle 7 (21 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from first documented confirmed response to first documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Part 2 only)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>Percent of patients who achieve iCR, partial response per iRECIST (iPR), or stable disease per iRECIST (iSD) at 18 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from first dose to first documented disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from first dose to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events and changes in clinical laboratory abnormalities (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence changes in clinical laboratory (Part 2 only)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1A - XTX101 Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1A Dose Escalation of XTX101 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B - Pharmacodynamic (PD) Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1B XTX101 at the RP2D will be administered to further examine XTX101 as monotherapy in patients with select advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1C - XTX101 Dose Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1C Standard labeled dose of pembrolizumab followed by administration of escalating doses of XTX101 to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2- XTX101 and Pembrolizumab Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 will examine XTX101 and pembrolizumab combination therapy at the RP2D in patients with unresectable or metastatic melanoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XTX101</intervention_name>
    <description>XTX101 monotherapy</description>
    <arm_group_label>Part 1A - XTX101 Monotherapy Dose Escalation</arm_group_label>
    <arm_group_label>Part 1B - Pharmacodynamic (PD) Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg administered every 3 weeks in combination with XTX101</description>
    <arm_group_label>Part 1C - XTX101 Dose Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 2- XTX101 and Pembrolizumab Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XTX101</intervention_name>
    <description>In combination with Pembrolizumab</description>
    <arm_group_label>Part 1C - XTX101 Dose Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 2- XTX101 and Pembrolizumab Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Criteria - Part 1A and 1C- Any histologically or cytologically confirmed solid&#xD;
             tumor malignancy that is locally advanced or metastatic and has failed standard&#xD;
             therapy, or standard therapy is not curative or available; Part 1B - Any&#xD;
             histologically or cytologically confirmed solid tumor malignancy for which anti-PD-1&#xD;
             or anti-PD-L1 treatment is approved and has progressed on or after prior anti-PD-1 or&#xD;
             anti-PD-L1 therapy. Part 2- histologically or cytologically confirmed unresectable or&#xD;
             metastatic melanoma that has not been treated with prior anti-PD-1 or anti-PD-L1&#xD;
             therapy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Part 2 only: measurable disease per iRECIST&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior treatment with anti-CTL-4 therapy&#xD;
&#xD;
          -  Received prior immune-checkpoint therapy and experienced Grade 3 or greater toxicity&#xD;
             lasting greater than 6 weeks&#xD;
&#xD;
          -  Received prior systemic anticancer therapy within 4 weeks prior to study treatment&#xD;
&#xD;
          -  Received prior radiotherapy within 2 weeks prior to study treatment&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency&#xD;
&#xD;
          -  Has known malignancy (other than disease under study) that is progressing or has&#xD;
             required active treatment within the past 3 years&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years,&#xD;
             including the use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy within 4 weeks prior to study&#xD;
             treatment&#xD;
&#xD;
          -  Has a history of severe hypersensitivity reaction (â‰¥ Grade 3) to any study&#xD;
             intervention and/or any of its excipients&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study&#xD;
&#xD;
          -  Part 2 only: has ocular melanoma&#xD;
&#xD;
          -  Part 2 only: has received prior anti-PD-1/L-1 therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teleen Norman</last_name>
    <phone>203-584-5310</phone>
    <email>tnorman@xiliotx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Huber, MD</last_name>
    <phone>857-524-2456</phone>
    <email>mhuber@xiliotx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Kaufman, MD</last_name>
      <phone>617-724-4000</phone>
      <email>hlkaufman@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley McClain Wallace</last_name>
      <phone>980-441-1021</phone>
      <email>amcclain@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>John Powderly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Next Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia DeLeon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Andrae Vandross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

